CDR3 Therapeutics is a pioneer in developing stem cell-based immunotherapies to revolutionize cancer treatment. The company's unique, patented technology overcomes the limitations of current CAR-T therapies, such as reduced functionality and persistence. By using hematopoietic stem cells (HSCs) sourced from patients and adding either CAR or TCR genes, CDR3 creates a self-renewing source of gene-targeted immune cells. The modified cells engrafted into the patient's bone marrow, maintain their performance over time, thus addressing the challenge of solid tumors, an area currently unmet by FDA-approved therapies.
